文献速递胸部肿瘤

局部晚期NSCLC同步放化疗中放疗剂量与靶区策略相关毒性:协作组试验汇总分析

Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-10-04

该汇总分析纳入16项协作组试验中3600例接受同步放化疗的局部晚期NSCLC患者个体数据,比较选择性淋巴结照射(ENI)与累及野放疗(IF-TRT)、以及60 Gy与>60 Gy的毒性差异。结果显示>60 Gy显著增加≥3级和≥4级不良事件,ENI与≥4级不良事件增多相关,而ENI与≥3级不良事件无显著关联。

要点

  • >60 Gy放疗显著增加≥3级和≥4级不良事件风险。
  • ENI较IF-TRT显著增加≥4级不良事件,但未增加≥3级不良事件。
  • 高剂量放疗与治疗相关死亡增加相关,ENI无此关联。

核心结论

  • 对于接受同步放化疗的LA-NSCLC患者,IF-TRT与ENI相比≥3级不良事件总体风险无显著差异,但≥4级不良事件显著更少。
  • 较高放疗剂量与≥3级、≥4级不良事件显著增加相关。
  • 结合既往生存报告,IF-TRT联合60 Gy(常规分割)与更优生存和更少毒性相关。

研究设计与样本

  • 汇总分析16项协作组同步放化疗试验中3600例LA-NSCLC患者的个体数据。
  • 考察的TRT参数包括靶区设计策略(ENI vs IF-TRT)和TRT剂量(60 Gy vs ≥60 Gy)。
  • 主要终点为不良事件发生,采用单变量和多变量logistic模型计算OR。

主要发现

  • TRT剂量范围为60至74 Gy。
  • ENI与IF-TRT相比≥3级不良事件的多变量OR=0.77(95%CI 0.543-1.102,p=0.1545),无显著差异。
  • >60 Gy与≥3级不良事件的多变量OR=1.82(95%CI 1.501-2.203,p<0.0001)。
  • ENI与≥4级不良事件的多变量OR=1.33(95%CI 1.035-1.709,p=0.0258)。
  • >60 Gy与≥4级不良事件的多变量OR=1.42(95%CI 1.191-1.700,p=0.0001)。

关键数值与推荐

  • ≥3级不良事件:ENI vs IF-TRT多变量OR=0.77(95%CI 0.543-1.102,p=0.1545)。
  • ≥3级不良事件:>60 Gy vs 60 Gy多变量OR=1.82(95%CI 1.501-2.203,p<0.0001)。
  • ≥4级不良事件:ENI vs IF-TRT多变量OR=1.33(95%CI 1.035-1.709,p=0.0258)。
  • ≥4级不良事件:>60 Gy vs 60 Gy多变量OR=1.42(95%CI 1.191-1.700,p=0.0001)。
  • 5级不良事件加治疗相关死亡在高剂量TRT更常见(p=0.0012),ENI无显著差异(p=0.099)。

临床怎么用

  • LA-NSCLC同步放化疗优先采用IF-TRT以降低≥4级不良事件风险。
  • 常规分割60 Gy较>60 Gy毒性更低,结合生存数据支持60 Gy作为优选剂量。
  • 避免常规使用ENI和高剂量TRT以减少严重毒性及治疗相关死亡。

局限性

  • 为汇总分析而非前瞻性随机对照,存在混杂因素可能。
  • 仅纳入协作组试验患者,结论外推需谨慎。
  • 不良事件报告标准可能在各试验间存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Concurrent chemoradiotherapy (CRT) was the standard treatment for locally advanced NSCLC (LA-NSCLC). This study was performed to examine thoracic radiotherapy (TRT) parameters and their impact on adverse events (AEs). METHODS: We collected individual patient data from 3600 patients with LA-NSCLC who participated in 16 cooperative group trials of concurrent CRT. The TRT parameters examined included field design strategy (elective nodal irradiation [ENI] versus involved-field [IF] TRT [IF-TRT]) and TRT dose (60 Gy versus ≥60 Gy). The primary end point of this analysis was the occurrence of AEs. ORs for AEs were calculated with univariable and multivariable logistic models. RESULTS: TRT doses ranged from 60 to 74 Gy. ENI was not associated with more grade 3 or higher AEs than IF-TRT was (multivariable OR = 0.77, 95% confidence interval [CI]: 0.543-1.102, p = 0.1545). Doses higher than 60 Gy (high-dose TRT) were associated with significantly more grade 3 or higher AEs (multivariable OR = 1.82, 95% CI: 1.501-2.203, p < 0.0001). In contrast, ENI was associated with significantly more grade 4 or higher AEs (multivariable OR = 1.33, 95% CI: 1.035-1.709, p = 0.0258). Doses higher than 60 Gy were also associated with more grade 4 or higher AEs (multivariate OR = 1.42, 95% CI: 1.191-1.700, p = 0.0001). Grade 5 AEs plus treatment-related deaths were more frequent with higher-dose TRT (p = 0.0012) but not ENI (p = 0.099). CONCLUSIONS: For patients with LA-NSCLC treated with concurrent CRT, IF-TRT was not associated with the overall risk of grade 3 or higher AEs but was associated with significantly fewer grade 4 or higher AEs than ENI TRT. This is likely the result of irradiation of a lesser amount of adjacent critical normal tissue. Higher TRT doses were associated significantly with grade 3 or higher and grade 4 or higher AEs. On the basis of these findings and our prior report on survival, CRT using IF-TRT and 60 Gy (conventionally fractionated) were associated with more favorable patient survival and less toxicity than was the use of ENI or higher radiotherapy doses.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Schild SE, Fan W, Stinchcombe TE, et al. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 30292852. doi:10.1016/j.jtho.2018.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。